Ekinci et al. demonstrated that de novo metastatic disease was not a poor prognostic marker for overall survival in patients with EGFR-mutant NSCLC who received EGFR-TKI treatment [28]. The gene discussed is EGFR; the disease is metastatic neoplasm.